PDCD1 and neoplasm: Furthermore, tumor PD-1 expression is not considered a useful predictor of the response to anti-PD-1 therapy, and in fact in patients with NSCLC – which accounts for the vast majority of lung malignancies – only tumoral PD-L1 is determined (with results being considered positive if expression levels >1%)12–14.